Study title:
Narimatsu H, Kami M, Kato D, Matsumura T, Murashige N, Kusumi E et al.
2007; Reduced dose of foscarnet as preemptive therapy for cytomegalovirus infection following reduced-intensity cord blood transplantation. Transplant Infectious Disease 2007; 9(1):11-15.Narimatsu H, Kami M, Kato D, Matsumura T, Murashige N, Kusumi E et al.
2007; Reduced dose of foscarnet as preemptive therapy for cytomegalovirus infection following reduced-intensity cord blood transplantation. Transplant Infectious Disease 2007; 9(1):11-15.
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area:
|
Brands: Please see report, Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: FOSCARNET |
ATC code: |
Document link:
Narimatsu H et al. 2007.pdf
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
-
|
Y
|